Eyestem moves closer to blindness breakthrough with phase 2 trial green light

The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity

EU green light to IntraBio’s AQNEURSA for rare neurological disease Niemann-Pick Type C

The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients

Sanofi’s Amlitelimab delivers in Phase 3 trials, heads for global filings

In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24

Trelegy Ellipta gets green light in China for adults with uncontrolled asthma

The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China

Bengaluru docs perform world’s first single-stage robotic heart bypass & prostate cancer surgery

Novo Medi Sciences unveils India’s next-generation varicella vaccine NEXIPOX PLUS

This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues

Functional Gut Clinic launches UK’s first boutique GI clinical trials division

Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced

Alteogen strikes $285M deal with GSK subsidiary for innovative cancer drug delivery

This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market

Bayer and Vanderbilt launch five-year partnership to accelerate innovative therapies

The partnership initially will focus on cardiovascular and kidney diseases

Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator

This marks the second indication for which gumokimab has gained NDA review acceptance